SEARCH:   Advanced

Blood, 1 November 2003, Vol. 102, No. 9, pp. 3340-3348. Prepublished online as a Blood First Edition Paper on July 10, 2003; DOI 10.1182/blood-2003-04-1338. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-04-1338v1 102/9/3340    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Vacca, A. Articles by Dammacco, F. Search for Related Content PubMed PubMed Citation Articles by Vacca, A. Articles by Dammacco, F. Related Collections Hemostasis, Thrombosis, and Vascular Biology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Endothelial cells in the bone marrow of patients with multiple myeloma Angelo Vacca, Roberto Ria, Fabrizio Semeraro, Francesca Merchionne, Mauro Coluccia, Angela Boccarelli, Claudio Scavelli, Beatrice Nico, Angela Gernone, Feliciana Battelli, Antonio Tabilio, Diego Guidolin, Maria Teresa Petrucci, Domenico Ribatti, and Franco Dammacco From the Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy; Department of Human Anatomy and Histology, University of Bari Medical School, Italy; Department of Clinical and Experimental Medicine, Section of Hematology and Immunology, University of Perugia Medical School, Italy; Department of Human Anatomy and Physiology, University of Padova Medical School, Italy; and Department of Cell Biotechnologies and Hematology, University of Rome Medical School, Italy. Endothelial cells (EC) were extracted through a lectin-based method from bone marrow of 57 patients with active multiple myeloma (MM) and compared with their healthy quiescent counterpart, human umbilical vein EC (HUVEC). MMECs exhibit specific antigens that indicate ongoing angiogenesis and embryo vasculogenesis; solid intercellular connections, hence stability of MM neovessels; and frequent interactions with plasma cells, hence tumor dissemination. They show heterogeneous antigen expression, hence existence of subsets. Their main genetic markers are indicative of a vascular phase. They show intrinsic angiogenic ability, because they rapidly form a capillary network in vitro, and extrinsic ability, because they generate numerous new vessels in vivo. They vividly secrete growth and invasive factors for plasma cells. They signal through kinases mandatory for development of neovascularization. Ultrastructurally, they are abnormal and show metabolic activation, like tumor ECs. Thalidomide heavily interferes with their functions. Vasculogenesis and angiogenesis might contribute to the MM vascular tree and progression, in the form of growth, invasion, and dissemination. In view of the heterogeneity of the antigenic phenotype of MMECs, a mixture (or a sequence) of antiangiogenic agents coupled with thalidomide would seem plausible for the biologic management of MM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873. [Abstract] [Full Text] [PDF] R. Ria, K. Todoerti, S. Berardi, A. M. L. Coluccia, A. De Luisi, M. Mattioli, D. Ronchetti, F. Morabito, A. Guarini, M. T. Petrucci, et al. Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma Clin. Cancer Res., September 1, 2009; 15(17): 5369 - 5378. [Abstract] [Full Text] [PDF] A. Pennisi, W. Ling, X. Li, S. Khan, J. D. Shaughnessy Jr, B. Barlogie, and S. Yaccoby The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth Blood, August 27, 2009; 114(9): 1803 - 1812. [Abstract] [Full Text] [PDF] D. Hose, J. Moreaux, T. Meissner, A. Seckinger, H. Goldschmidt, A. Benner, K. Mahtouk, J. Hillengass, T. Reme, J. De Vos, et al. Induction of angiogenesis by normal and malignant plasma cells Blood, July 2, 2009; 114(1): 128 - 143. [Abstract] [Full Text] [PDF] A. M. L. Coluccia, T. Cirulli, P. Neri, D. Mangieri, M. C. Colanardi, A. Gnoni, N. Di Renzo, F. Dammacco, P. Tassone, D. Ribatti, et al. Validation of PDGFR{beta} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib Blood, August 15, 2008; 112(4): 1346 - 1356. [Abstract] [Full Text] [PDF] R. Ria, C. Piccoli, T. Cirulli, F. Falzetti, G. Mangialardi, D. Guidolin, A. Tabilio, N. Di Renzo, A. Guarini, D. Ribatti, et al. Endothelial Differentiation of Hematopoietic Stem and Progenitor Cells from Patients with Multiple Myeloma Clin. Cancer Res., March 15, 2008; 14(6): 1678 - 1685. [Abstract] [Full Text] [PDF] C. Scavelli, G. Di Pietro, T. Cirulli, M. Coluccia, A. Boccarelli, T. Giannini, G. Mangialardi, R. Bertieri, A. M. L. Coluccia, D. Ribatti, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma Mol. Cancer Ther., December 1, 2007; 6(12): 3256 - 3262. [Abstract] [Full Text] [PDF] K. Sukhdeo, M. Mani, Y. Zhang, J. Dutta, H. Yasui, M. D. Rooney, D. E. Carrasco, M. Zheng, H. He, Y.-T. Tai, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma PNAS, May 1, 2007; 104(18): 7516 - 7521. [Abstract] [Full Text] [PDF] M. Chatterjee, S. Jain, T. Stuhmer, M. Andrulis, U. Ungethum, R.-J. Kuban, H. Lorentz, K. Bommert, M. Topp, D. Kramer, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90{alpha} and {beta} in multiple myeloma cells, which critically contribute to tumor-cell survival Blood, January 15, 2007; 109(2): 720 - 728. [Abstract] [Full Text] [PDF] A. Vacca, C. Scavelli, G. Serini, G. Di Pietro, T. Cirulli, F. Merchionne, D. Ribatti, F. Bussolino, D. Guidolin, G. Piaggio, et al. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma Blood, September 1, 2006; 108(5): 1661 - 1667. [Abstract] [Full Text] [PDF] G. M. Rigolin, C. Fraulini, M. Ciccone, E. Mauro, A. M. Bugli, C. De Angeli, M. Negrini, A. Cuneo, and G. Castoldi Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion Blood, March 15, 2006; 107(6): 2531 - 2535. [Abstract] [Full Text] [PDF] A. M. Roccaro, T. Hideshima, N. Raje, S. Kumar, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Ribatti, B. Nico, A. Vacca, et al. Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells Cancer Res., January 1, 2006; 66(1): 184 - 191. [Abstract] [Full Text] [PDF] L. F. Costa, M. Balcells, E. R. Edelman, L. M. Nadler, and A. A. Cardoso Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-{kappa}B Blood, January 1, 2006; 107(1): 285 - 292. [Abstract] [Full Text] [PDF] H. Yasui, T. Hideshima, N. Raje, A. M. Roccaro, N. Shiraishi, S. Kumar, M. Hamasaki, K. Ishitsuka, Y.-T. Tai, K. Podar, et al. FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance Cancer Res., August 15, 2005; 65(16): 7478 - 7484. [Abstract] [Full Text] [PDF] A. Vacca, C. Scavelli, V. Montefusco, G. Di Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco, et al. Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma J. Clin. Oncol., August 10, 2005; 23(23): 5334 - 5346. [Abstract] [Full Text] [PDF] A. Vacca New aspects of myeloma management Blood, July 15, 2005; 106(2): 395 - 395. [Full Text] [PDF] M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo Blood, June 1, 2005; 105(11): 4470 - 4476. [Abstract] [Full Text] [PDF] H. Zhang, V. Vakil, M. Braunstein, E. L. P. Smith, J. Maroney, L. Chen, K. Dai, J. R. Berenson, M. M. Hussain, U. Klueppelberg, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood, April 15, 2005; 105(8): 3286 - 3294. [Abstract] [Full Text] [PDF] K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF] B. Streubel, A. Chott, D. Huber, M. Exner, U. Jager, O. Wagner, and I. Schwarzinger Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas N. Engl. J. Med., July 15, 2004; 351(3): 250 - 259. [Abstract] [Full Text] [PDF] K. Asosingh, H. De Raeve, E. Menu, I. Van Riet, E. Van Marck, B. Van Camp, and K. Vanderkerken Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity Blood, April 15, 2004; 103(8): 3131 - 3137. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020